Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.
Nuvalent has raised $500.0M in total funding. The most recent round was Post-IPO Secondary. The last funding was announced in November 2025.
Nuvalent's investors include Janus Henderson Investors, Wellington Management, Bain Capital Life Sciences, Fidelity, Deerfield.
Nuvalent is headquartered in Cambridge, United States.
Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.
Nuvalent is at the Post-IPO Secondary stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuvalent — Funding & Investors." VCBacked, November 18, 2025, https://www.vcbacked.co/company/nuvalent. Accessed August 14, 2026.
VCBacked. (2025). Nuvalent — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nuvalent
{{cite web |title=Nuvalent — Funding & Investors |url=https://www.vcbacked.co/company/nuvalent |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated